Registered number: 08229467
Charity number: 1152591

HAEUK

(A company limited by guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2025

HAEUK

(A company limited by guarantee)

CONTENTS

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 30 SEPTEMBER 2025

Trustees

Company registered number

08229467

Charity registered number

1152591

Accountants

GMBC LLP
Chartered Tax Advisers and Accountants
Marine House
151 Western Road
Haywards Heath
West Sussex
RH16 3LH

TRUSTEES' REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2025

The Trustees present their annual report together with the financial statements of the company for the period 1 October 2024 to 30 September 2025. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the company qualifies as small under section 382 of the Companies Act 2006, the Strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

Objectives and activities

a. Policies and objectives

The main purpose of the charity is to promote and protect the physical and mental health of sufferers of Hereditary Angioedema in the United Kingdom through the provision of support, education and practical advice and to advance the education of the general public in all areas of the condition.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

b. Activities undertaken to achieve objectives

HAEUK has identified the following activities to promote the achievement of its objectives:

- To ensure the UK has the highest possible standards of treatment for HAE
- To provide patient advocacy and support, arranging periodic Patient Meetings, and maintaining and enhancing the website.
- To make representations on various NHS consultation processes and to medical professionals and their professional bodies.
- To commission the production and dissemination of best practice documentation for the management of HAE.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025

Achievements and performance

a. Review of activities

2025 was a year of new developments in the treatment and management of HAE with a number of products going through clinical trial and then the MHRA and NICE approval process. A long journey but with one new treatment now approved for use in the NHS, several more are in the latter stage and the choices for patients continues to grow and improve.

The CEO was involved in a large number of meetings throughout the last financial year in making representations on behalf of the patient community, together with giving expert advice alongside several of the Trustees.

The Shared Decision Making "Power of Partnership" programme funded by BioCryst was a huge success and nearly all clinicians in the UK now adopt a very positive attitude to working jointly with patients, enabling patients themselves to also feel more involved when making choices about treatments.

The CEO also attended the Immunology and Allergy Nurses Group in Birmingham, visited several clinics, visited offices of some of the pharmaceutical companies and had many meetings with the Clinical Reference Group for Immunology and Allergy, with Genetic Alliance and Rare Disease UK.

In addition, the CEO and several Trustees attended the HAEi Conference in Copenhagen, the Rare Disease Day event organised by Genetic Alliance at the House of Commons, and the European Association of Allergy and Clinical Immunology annual conference in Glasgow.

b. Fundraising activities and income generation

The primary source of income remains donations from pharmaceutical companies following submission of the necessary business plans to them. Other funding includes Foundation and members fundraising events.

Financial review

a. Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.

b. Reserves policy

It is the policy of the Trustees to maintain a level of reserves sufficient to cover 3 months anticipated expenditure. At 30 September 2025 the level of reserves was consistent with this policy.

c. Principal funding

Donations from pharmaceutical companies remains the primary source of funding. However have secured additional funding from a Foundation Trust.

Structure, governance and management

a. Constitution

HAEUK is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association.

It is exempt from the use of the word 'limited'.

b. Methods of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and co-opted under the terms of the Articles of Association.

Plans for future periods

HAEUK will continue to encourage patients and the wider public to fundraise eg, by way of donations, sponsorship, and regular/payroll giving in order to broaden the scope of its funding sources.

HAEUK will to update/produce a range of policies to formalize its operating arrangements etc; together with developing a secure data storage/filing system.

A comprehensive update of its website will be finalized, including working towards a specific member's only section.

HAEUK will aim to focus more on the needs of children and young people and envisage that volunteers will play an increasing role in this process.

HAEUK is proposing to extend its influence and support to patients in other parts of the United Kingdom.

The trustees will keep HAEUK's 5 Year Strategic Plan under review and updated.

Members' liability

The Members of the company guarantee to contribute an amount not exceeding £1 to the assets of the company in the event of winding up.

Statement of Trustees' responsibilities

The Trustees (who are also the directors of the company for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on Apr 28, 2026 and signed on their behalf by:

A harding

Ann Marie Harding
(Chair of Trustees)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 30 SEPTEMBER 2025

Independent examiner's report to the Trustees of ('the company')

I report to the charity Trustees on my examination of the accounts of the company for the year ended 30 September 2025.

Responsibilities and basis of report

As the Trustees of the company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the company's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the company and the company's Trustees as a body, for my work or for this report.

Signed: Graham Hole Dated: 28 April 2026

Graham Hole

GMBC LLP
Chartered Tax Advisers and Accountants
Marine House
151 Western Road
Haywards Heath
West Sussex
RH16 3LH

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 30 SEPTEMBER 2025

	Note	Unrestricted funds 2025 £	Total funds 2025 £	*Total funds 2024 £*
Income from:				
Donations and legacies	3	102,670	102,670	*73,100*
Total income		102,670	102,670	*73,100*
Expenditure on:				
Charitable activities	4	120,280	120,280	*129,363*
Total expenditure		120,280	120,280	*129,363*
Net movement in funds		(17,610)	(17,610)	*(56,263)*
Reconciliation of funds:				
Total funds brought forward		122,291	122,291	*178,554*
Net movement in funds		(17,610)	(17,610)	*(56,263)*
Total funds carried forward		104,681	104,681	*122,291*

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 10 to 20 form part of these financial statements.

HAEUK

(A company limited by guarantee)
REGISTERED NUMBER: 08229467

BALANCE SHEET
AS AT 30 SEPTEMBER 2025

	Note		2025 £		2024 £
Fixed assets					
Tangible assets	8		**1,784**		*2,231*
			1,784		*2,231*
Current assets					
Cash at bank and in hand		**109,535**		*125,604*	
		109,535		*125,604*	
Current liabilities					
Creditors: amounts falling due within one year	9	**(6,638)**		*(5,544)*	
Net current assets			**102,897**		*120,060*
Total assets less current liabilities			**104,681**		*122,291*
Total net assets			**104,681**		*122,291*
Charity funds					
Restricted funds	11		-		-
Unrestricted funds	11		**104,681**		*122,291*
Total funds			**104,681**		*122,291*

BALANCE SHEET (CONTINUED)
AS AT 30 SEPTEMBER 2025

The company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on 28th April 2026 and signed on their behalf by:

A harding

Ann Marie Harding
(Chair of Trustees)

The notes on pages 10 to 20 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025

1. General information

HAEUK is a private company, limited by guarantee, domiciled in England and Wales, registration number 08229467. The registered charity number is 1152591. The registered office of the company is 2 Sheridan Close, Bridgwater, Somerset, TA6 5SN.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

HAEUK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the company's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

2. Accounting policies (continued)

2.4 Tangible fixed assets and depreciation

Tangible fixed assets costing £100 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Office equipment	-	20%

2.5 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.6 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

2. Accounting policies (continued)

2.7 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025

3. Income from donations and legacies

	Unrestricted funds 2025 £	Total funds 2025 £	*Total funds 2024 £*
Donations			
CSL Behring	30,375	**30,375**	-
The Anderson Foundation	16,500	**16,500**	*16,500*
KalVista Pharmaceuticals	10,000	**10,000**	-
HAE international	32,285	**32,285**	*17,428*
BioCryst Pharmaceuticals	10,600	**10,600**	*20,150*
University Hospital Birmingham	-	-	*13,030*
Subtotal detailed disclosure	99,760	**99,760**	*67,108*
Donations	2,910	**2,910**	*5,992*
Subtotal	2,910	**2,910**	*5,992*
Total 2025	102,670	**102,670**	*73,100*
Total 2024	*73,100*	*73,100*	

4. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2025 £	Total 2025 £	*Total 2024 £*
Support and education to help sufferers of Hereditary Angioedema in the UK	120,280	**120,280**	*129,363*
Total 2024	*129,363*	*129,363*	

5. Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Support costs 2025 £	Total funds 2025 £	*Total funds 2024 £*
Support and education to help sufferers of Hereditary Angioedema in the UK	32,657	87,622	**120,279**	*129,363*
Total 2024	*39,206*	*90,157*	*129,363*	

5. Analysis of expenditure by activities (continued)

Analysis of direct costs

	Activities 2025 £	**Total funds 2025 £**	*Total funds 2024 £*
Patient survey costs	5,919	**5,919**	*2,096*
Virtual patient days	-	**-**	*1,892*
Research into the lived experience of Hereditary Angioedema	26,739	**26,739**	*28,738*
Costs of activity-Campaign cost	-	**-**	*6,480*
Other	(1)	**(1)**	*-*
Total 2025	32,657	**32,657**	*39,206*
Total 2024	*39,206*	*39,206*	

5. Analysis of expenditure by activities (continued)

Analysis of support costs

	Activities 2025 £	**Total funds 2025 £**	*Total funds 2024 £*
Depreciation	446	**446**	*558*
Communication costs	431	**431**	*398*
Website costs	2,118	**2,118**	*5,046*
Postage, printing and stationery	800	**800**	*2,713*
Travel and subsistence	772	**772**	*8,684*
Training & Seminar	4,813	**4,813**	*-*
Subscription costs	466	**466**	*1,489*
CEO consultancy fees	45,380	**45,380**	*36,575*
EO consultancy fees	14,855	**14,855**	*15,180*
Sundry expenses	524	**524**	*316*
Advertising & marketing cost	14,644	**14,644**	*-*
Insurance	201	**201**	*201*
Accountancy fees	1,302	**1,302**	*1,421*
Film production	-	**-**	*16,605*
IT software and consumables	820	**820**	*971*
Design services	50	**50**	*-*
Total 2025	87,622	**87,622**	*90,157*
Total 2024	*90,157*	*90,157*	

6. Independent examiner's remuneration

	2025 £	*2024 £*
Fees payable to the company's independent examiner for the independent examination of the company's annual accounts	**960**	*960*
Fees payable to the company's independent examiner in respect of:		
All other services not included above	**318**	*294*

7. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits *(2024 - £NIL)*.

During the year ended 30 September 2025, expenses totalling £1,260 were reimbursed or paid directly to 3 Trustees. The expenses related to travel cost and HAE survey cost.

8. Tangible fixed assets

	Office equipment £
Cost or valuation	
At 1 October 2024	8,711
At 30 September 2025	8,711
Depreciation	
At 1 October 2024	6,480
Charge for the year	446
At 30 September 2025	6,926
Net book value	
At 30 September 2025	1,785
At 30 September 2024	*2,230*

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025

9. Creditors: Amounts falling due within one year

	2025 £	*2024 £*
Accruals and deferred income	6,638	*5,544*

10. Financial instruments

	2025 £	*2024 £*
Financial assets		
Financial assets measured at amortised cost	109,535	*125,604*

	2025 £	*2024 £*
Financial liabilities		
Financial liabilities measured at amortised cost	(6,638)	*(5,544)*

Financial assets measured at amortised cost comprises cash at bank and in hand.

Financial liabilities measured at amortised cost comprises accruals.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025**

11. Statement of funds

Statement of funds - current year

	Balance at 1 October 2024 £	Income £	Expenditure £	Balance at 30 September 2025 £
Unrestricted funds				
General Funds - all funds	**122,291**	**102,670**	**(120,280)**	**104,681**

Statement of funds - prior year

	Balance at 1 October 2023 £	*Income £*	*Expenditure £*	*Balance at 30 September 2024 £*
Unrestricted funds				
General Funds - all funds	*178,554*	*73,100*	*(129,363)*	*122,291*

12. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2025 £	Total funds 2025 £
Tangible fixed assets	1,784	**1,784**
Current assets	109,535	**109,535**
Creditors due within one year	(6,638)	**(6,638)**
Total	104,681	**104,681**

Analysis of net assets between funds - prior year

	Unrestricted funds 2024 £	*Total funds 2024 £*
Tangible fixed assets	*2,231*	*2,231*
Current assets	*125,604*	*125,604*
Creditors due within one year	*(5,544)*	*(5,544)*
Total	*122,291*	*122,291*